Back

Clinical outcomes by prior OAC use and switching to edoxaban in atrial fibrillation: 2-year follow-up data from the ETNA-AF China study

28 August 2026 (16:15 - 16:45)
Organised by: Logo
Congress Presentation Part of: Balancing stroke prevention and bleeding risk in atrial fibrillation Oral Anticoagulation ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Chang-Sheng Ma

Beijing Anzhen Hospital, Beijing (China)

4 More presentations in this session

Presentation thumbnail
Clinical determinants of oral anticoagulant selection in atrial fibrillation: insights from an Argentine registry
Doctor M. Trivi (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Left atrial appendage occlusion versus oral anticoagulation in frail patients with atrial fibrillation: a real-world study
Professor T. Liu (Tianjin, CN)
Presentation thumbnail
Association of antithrombotic therapy with cerebral microbleeds: a cross-sectional, multicentre analysis
Mr J. Gruthoelter (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Predictors of major bleeding events among Chinese patients receiving edoxaban for atrial fibrillation at 2-year follow-up
Professor C. Ma (Beijing, CN)

Access the full session

Session thumbnail
Balancing stroke prevention and bleeding risk in atrial fibrillation

The Event

Event poster

ESC Congress 2026

28 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study
25 April 2021
thumbnail
Congress Presentation
Clinical impact of switching or continuation of apixaban or rivaroxaban among patients with non-valvular atrial fibrillation
25 August 2023
thumbnail
Congress Presentation
Meta-analysis on the comparison of direct oral anticoagulants versus vitamin k antagonists after transcatheter aortic valve implantation in patients with pre-existing atrial fibrillation
26 August 2022
thumbnail
Congress Presentation
Anticoagulation in patients with new-onset atrial fibrillation after acute coronary syndrome
29 June 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources